Reprogramming of human fibroblasts to induced pluripotent stem cells under xeno-free conditions


Autoria(s): Rodríguez Pizà, Ignasi; Vassena, Rita; Richaud Patin, Yvonne; Izpisúa Belmonte, J. C.; Raya Chamorro, Ángel; Veiga, Anna; Barrero, María José; González, Federico
Data(s)

02/07/2013

Resumo

The availability of induced pluripotent stem cells (iPSCs)has created extraordinary opportunities for modeling andperhaps treating human disease. However, all reprogrammingprotocols used to date involve the use of products of animal origin. Here, we set out to develop a protocol to generate and maintain human iPSC that would be entirelydevoid of xenobiotics. We first developed a xeno-free cellculture media that supported the long-term propagation of human embryonic stem cells (hESCs) to a similar extent as conventional media containing animal origin products or commercially available xeno-free medium. We also derivedprimary cultures of human dermal fibroblasts under strictxeno-free conditions (XF-HFF), and we show that they can be used as both the cell source for iPSC generation as well as autologous feeder cells to support their growth. We also replaced other reagents of animal origin trypsin, gelatin, matrigel) with their recombinant equivalents. Finally, we used vesicular stomatitis virus G-pseudotyped retroviral particles expressing a polycistronic construct encoding Oct4, Sox2, Klf4, and GFP to reprogram XF-HFF cells under xeno-free conditions. A total of 10 xeno-free humaniPSC lines were generated, which could be continuously passaged in xeno-free conditions and aintained characteristics indistinguishable from hESCs, including colonymorphology and growth behavior, expression of pluripotency-associated markers, and pluripotent differentiationability in vitro and in teratoma assays. Overall, the resultspresented here demonstrate that human iPSCs can be generatedand maintained under strict xeno-free conditions and provide a path to good manufacturing practice (GMP) applicability that should facilitate the clinical translation of iPSC-based therapies.

Identificador

http://hdl.handle.net/10230/12429

Idioma(s)

eng

Publicador

AlphaMed Press and Wiley-Blackwell

Direitos

© 2011 AlphaMed Press

info:eu-repo/semantics/openAccess

Palavras-Chave #Medicina regenerativa #Cél·lules mare embrionàries #Cell culture #Clinical translation #Embryonic stem cells #iPS cells #Good manufacturing practice
Tipo

info:eu-repo/semantics/article

info:eu-repo/semantics/publishedVersion